Journal of Information Systems Engineering and Management
2025, 10(60s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/

Research Article

A Graph + NLP Framework to Identify Influential HCPs for Pharmaceutical Launches: Design, Deployment, and Managerial Impact

Badal Shah
Neolytica - A QPharma Company, USA

ARTICLE INFO

Received: 12 Aug 2025

Revised: 14 Sept 2025

Accepted: 23 Sept 2025

ABSTRACT

Rapid and credible dissemination of scientific evidence is pivotal to modern medicine launches. Traditional Key-Opinion-Leader (KOL) programmes depend on narrow expert lists drawn from publication counts or prescribing volume, overlooking the relational and attitudinal pathways through which influence actually propagates. This article presents an end-to-end framework that fuses multi-layer network analytics built on medical-digital platforms, embeds a human-in-the-loop sentiment-surveillance pipeline, and ranks KOL sub-networks by propagative influence and sentiment trajectory. The innovative approach integrates three core technological components: multi-layer network analytics, human-in-the-loop sentiment surveillance, and propagative influence ranking. By assembling a comprehensive multi-layer graph incorporating diverse influence signals across scientific activity, professional collaboration, digital footprint, and real-world care delivery, the framework creates dynamic, evidence-optimized engagement maps. Empirical validation across international launches in immuno-oncology, antiviral therapy, and rare metabolic disease demonstrates consistent performance advantages in prescriber uptake velocity, field-team cost efficiency, and prescription generation. Implementation requires cross-functional governance, quarterly refresh cadence, integrated dashboards, and robust compliance safeguards to maximize impact while ensuring appropriate governance.

Keywords: Network analytics, sentiment analysis, healthcare influence, pharmaceutical launches, opinion leader identification

1. Executive Summary

Pharmaceutical drug launches represent critical inflection points where scientific evidence must be rapidly and credibly disseminated throughout healthcare networks. Traditional Key Opinion Leader (KOL) identification methodologies have historically relied on simplistic metrics that fail to capture the multifaceted nature of influence in healthcare settings. Research has shown that conventional approaches often prioritize high-volume prescribers and prolific academic publishers while overlooking the nuanced relational dynamics through which medical influence actually propagates across professional communities [1]. These traditional methods, which frequently depend on publication metrics and prescription data alone, create significant blind spots in launch strategies, potentially missing crucial influence pathways that operate through peer-to-peer interactions, digital engagement, and informal clinical networks.

This article examines an innovative end-to-end framework that fuses multi-layer network analytics built on thousands of medical-digital platforms. The system embeds a human-in-the-loop sentiment-surveillance pipeline utilizing hundreds of medical analysts and millions of expert-labeled statements to create a comprehensive influence mapping system. By ranking KOL sub-networks by propagative influence and sentiment trajectory, the approach creates a dynamic picture of how medical opinions form and spread throughout professional communities. The methodology represents a significant departure from conventional approaches, transitioning from static lists to dynamic, evidence-

Journal of Information Systems Engineering and Management
2025, 10(60s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/
Research Article

optimized engagement maps that capture a substantially higher percentage of clinically relevant opinion leaders across various specialties.

The framework's integration of social network analysis with pharmaceutical marketing strategy aligns with emerging research demonstrating that influence patterns in healthcare follow complex network principles rather than hierarchical structures. As noted in recent literature, healthcare professional networks exhibit characteristic patterns of information diffusion that can be modeled through network science approaches, allowing for more sophisticated targeting of educational initiatives [2]. By integrating real-time digital discourse analysis with traditional scientific metrics, the system processes clinician interactions continuously to maintain current influence assessments.

Across three international drug launches encompassing tens of thousands of clinically active physicians, this network-based approach has demonstrated substantial commercial advantages. Prescriber uptake velocity increased significantly compared to traditional targeting methods, with the time-to-adoption threshold decreasing by nearly a third. Concurrently, field-team engagement costs were reduced by approximately one-third per incremental adopter, representing millions in operational savings across the launch cycle. Perhaps most notably, networks led by positively trending KOLs generated many times more prescriptions per leader than their negative-sentiment counterparts, illustrating the critical importance of attitudinal factors in influence propagation.

The pharmaceutical launch landscape continues to evolve rapidly, with increasing therapeutic complexity requiring more sophisticated educational approaches. The average new molecular entity launch now necessitates understanding of substantially more mechanism-of-action data points than launches from the previous decade, placing greater emphasis on effective knowledge dissemination strategies. This combined network-and-sentiment methodology provides an adaptable framework for optimizing future launch strategies in an increasingly fragmented healthcare landscape, where digital engagement and peer influence play increasingly central roles in adoption decisions.

2. The Limitations of Traditional KOL Identification

As therapeutic mechanisms become increasingly complex and stakeholder ecosystems more fragmented, pharmaceutical companies face mounting challenges in effectively targeting the right clinicians with the right evidence at optimal times. The landscape of medical influence has evolved dramatically in recent years, yet many organizations continue to rely on outdated identification methodologies that fail to capture the nuanced reality of how medical opinions form and propagate throughout professional communities.

Legacy approaches to KOL identification have traditionally emphasized quantitative metrics that are easily measured but often poorly correlated with actual influence capacity. There exists a pervasive over-reliance on publication metrics and prescription volume data, creating a fundamental disconnect between identified "thought leaders" and genuine clinical influencers. As documented in comprehensive industry analyses, these simplistic bibliometric approaches frequently identify academics with impressive publication records but limited practical influence on prescribing behaviors among their peers [3]. The quantifiable nature of publication counts has made them an attractive but ultimately insufficient proxy for the multidimensional concept of influence in medical communities.

This methodological limitation leads to a troubling tendency within pharmaceutical launch teams to recycle familiar experts across multiple therapeutic areas, inadvertently creating echo chambers that limit message penetration and diversity of clinical perspective. Research examining KOL engagement patterns across multiple therapeutic launches has revealed that approximately two-thirds of pharmaceutical companies repeatedly engage the same limited cohort of established experts, even when launching in adjacent or novel therapeutic categories where fresh perspectives might prove more valuable [4]. This recycling effect creates a self-reinforcing system where visibility begets additional visibility, without necessarily corresponding to genuine influence on clinical practice.

Journal of Information Systems Engineering and Management
2025, 10(60s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/
Research Article

Another critical shortcoming of traditional approaches is their failure to account for attitudinal diversity and sentiment trajectories among potential opinion leaders. Static identification methodologies typically assess credentials and reach while ignoring the evolving sentiments these individuals hold toward specific therapeutic approaches or product classes. This one-dimensional view neglects the fundamental reality that influence effectiveness is heavily modulated by attitudinal factors—positive sentiment amplifies message adoption, while negative sentiment can actively suppress it regardless of the messenger's credentials or reach.

Perhaps most significantly, conventional KOL identification provides remarkably limited insight into the actual influence pathways between healthcare professionals. Traditional approaches treat influence as an individual attribute rather than a relational phenomenon that exists within complex professional networks. Without mapping the channels through which information and opinion actually flow between clinicians, pharmaceutical companies remain blind to the cascading effects of their educational initiatives and cannot effectively orchestrate the multi-step influence journeys that drive widespread clinical adoption.



Figure 1: Limitations of Traditional KOL Identification [3, 4]

3. A Multi-Dimensional Network Framework

The innovative framework presented in this article integrates three core technological components that work in concert to revolutionize how pharmaceutical companies identify and engage influential healthcare professionals. This comprehensive approach represents a significant advancement beyond traditional methods by combining sophisticated network science with artificial intelligence and human expertise.

At the foundation of this framework lies multi-layer network analytics built on data from over 100,000 medical-digital platforms. This expansive data collection enables unprecedented visibility into the complex web of relationships and interactions that define influence within medical

Journal of Information Systems Engineering and Management
2025, 10(60s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/ **Research Article**

communities. The analytical approach draws inspiration from advances in complex network theory that have transformed an understanding of how information propagates through professional communities, allowing for more nuanced mapping of influence pathways than ever before possible [5]. By applying these network science principles to the pharmaceutical launch context, companies can visualize the intricate channels through which clinical opinions and practice changes actually flow.
The second critical component is a human-in-the-loop sentiment surveillance system that combines the expertise of 300 medical analysts with state-of-the-art large language model automation. This hybrid approach acknowledges that while artificial intelligence offers remarkable efficiency in processing vast amounts of content, the nuanced interpretation of clinical discourse still benefits substantially from human medical expertise. The collaborative human-AI workflow enables comprehensive monitoring of expert sentiment across the therapeutic landscape, providing launch teams with unprecedented visibility into the evolving attitudes that modulate influence effectiveness.
The third component, propagative influence ranking, represents perhaps the most significant departure from traditional KOL identification methodologies. Rather than treating influence as an individual attribute, this approach conceptualizes it as a dynamic network property that must be calculated through sophisticated algorithms that account for both direct and indirect connections between healthcare professionals. This perspective aligns with contemporary network diffusion research demonstrating that influence potential depends not merely on an individual's credentials or reach, but on their specific position within professional networks that facilitate or impede information flow [6].

3.1 Data Enrichment & Influence-Mapping Foundations

The approach assembles a comprehensive multi-layer graph incorporating diverse influence signals across four primary data layers. The scientific activity layer draws from established sources, including PubMed®, Embase®, ClinicalTrials.gov, and congress proceedings to establish baseline metrics of peer credibility and topic authority. This foundation provides essential context about each clinician's formal contributions to the scientific discourse surrounding the therapeutic area.
Building upon this scientific foundation, the professional collaboration layer incorporates relationship data from shared authorship, trial sites, committees, co-employment, and common training pathways. These connections map the trust ties and knowledge flow channels that facilitate the informal exchange of clinical insights and practice recommendations. The inclusion of these professional relationships acknowledges that influence often travels through personal connections that may not be evident in publication records alone.
The digital footprint layer represents a particularly innovative aspect of the framework, aggregating data from over 100,000 platforms, including webinars, conference micro-blogging, podcast transcripts, closed clinician networks, and continuing medical education fora. This comprehensive digital surveillance enables measurement of real-time discourse reach and sentiment, providing a dynamic view of influence as it evolves through ongoing professional conversations across multiple channels.
The final layer, focused on real-world care delivery, utilizes de-identified claims data revealing patients-in-common, referral patterns, co-practice relationships, and prescription similarity. These practical diffusion channels in clinical settings often represent the most direct pathways through which practice changes propagate, making them essential components of a comprehensive influence map. By incorporating these real-world practice patterns, the framework captures influence relationships that manifest in actual clinical decision-making rather than merely academic discourse.
These diverse edge types are harmonized into a coherent multi-layer graph structure through sophisticated data integration techniques. Probabilistic edge-weight calibration precedes the application of personalized PageRank computation, a process that accounts for both the strength and type of connections between clinicians. This computational approach ultimately yields a propagative-influence score for each clinician in the network, quantifying their potential to drive message adoption among their peers.

Journal of Information Systems Engineering and Management
2025, 10(60s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/

Research Article

3.2 Sentiment Analysis Architecture

The sentiment analysis module combines human expertise with machine learning in a sophisticated pipeline that processes vast amounts of professional medical discourse. The training phase begins with a substantial human investment, as 300 medically trained analysts annotate millions of statements drawn from digital sources across the healthcare landscape. These annotations capture not only basic polarity (Positive/Neutral/Negative) but also crucial nuances, including strength of endorsement, specific safety concerns, and competitive preferences. This detailed annotation schema enables much more sophisticated sentiment analysis than generic approaches, accounting for the specialized language and contextual subtleties of clinical discourse.

An indication-tuned large language model is then fine-tuned on this extensively annotated corpus, developing specialized capabilities for interpreting the technical jargon and nuanced debates that characterize professional medical communication. This specialized training enables the model to distinguish between subtle gradations of clinical sentiment that would be indistinguishable to general-purpose language models lacking domain expertise.

In the production workflow, the tuned language model automatically classifies approximately 80% of new content with high confidence levels exceeding 95% accuracy. This automation dramatically increases the scalability of sentiment surveillance, enabling comprehensive monitoring across thousands of digital platforms simultaneously. For the remaining 20% of content—typically consisting of ambiguous, highly technical, or linguistically complex items—the system automatically routes the material back to human analysts for expert adjudication. These human-adjudicated items are then fed back into the training dataset, creating a virtuous learning loop that continually improves the system's recall and precision across increasingly specialized clinical contexts.

The final critical step involves integration with the influence scores derived from network analysis. Quarterly sentiment vectors are merged with propagative-influence rankings to create a dual-axis targeting matrix that guides strategic resource allocation. This integrated view enables launch teams to focus their highest-value resources on high-influence/positive-sentiment clusters that offer the greatest potential return on engagement investment. Simultaneously, the framework supports the development of bespoke scientific engagement plans for neutral or negative leaders whose influence potential merits specialized attention despite their current attitudinal positioning. This nuanced approach to engagement prioritization represents a significant advancement over traditional methods that lack the capacity to differentiate between influencers based on their evolving sentiment trajectories.



Fig 2: Multi-Dimensional Network Framework for KOL Identification [5, 6]

Journal of Information Systems Engineering and Management
2025, 10(60s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/
Research Article

4. Empirical Validation

The multi-dimensional network framework underwent rigorous empirical validation across three distinct therapeutic areas representing different market dynamics and adoption challenges. The evaluation encompassed immuno-oncology, characterized by complex mechanisms of action and specialized prescriber base; antiviral therapy in a pandemic context, notable for its accelerated adoption timeline and heightened stakeholder scrutiny; and rare metabolic disease, distinguished by its limited patient population and highly specialized care pathways. This diverse selection of therapeutic contexts was deliberately chosen to test the framework's adaptability across varying market conditions and adoption barriers, following methodological principles established in pharmaceutical launch effectiveness research [7].

The study population included approximately 72,000 clinically active physicians across these therapeutic indications, representing a comprehensive cross-section of the relevant prescriber ecosystems. To establish meaningful comparisons, the evaluation employed two control methodologies widely used in contemporary pharmaceutical launch planning: traditional publication-based top-50 lists derived from bibliometric analysis, and high-volume prescriber targeting approaches based on historical prescription data in adjacent therapeutic categories. These comparators were selected to represent the predominant identification methodologies currently employed by most pharmaceutical companies, allowing for direct assessment of the network-based approach's incremental value over existing industry standards.

The methodological approach to evaluation was designed to isolate the specific impact of the network-based identification framework while controlling for potential confounding variables. Quantitative assessment employed multi-stage data collection across pre-launch, launch, and post-launch phases to establish reliable baseline metrics and capture longitudinal performance trajectories. This temporal dimension proved particularly important for differentiating between immediate adoption effects and sustained practice change—a distinction often overlooked in pharmaceutical launch evaluations but critical for assessing genuine influence impact rather than merely temporary attention effects.

4.1 Key Performance Indicators

The evaluation framework centered on three critical outcomes selected to comprehensively assess both commercial impact and educational effectiveness. Uptake velocity, defined as the slope of cumulative prescribers over the first 12 months post-launch, provided a direct measure of adoption momentum and market penetration efficiency. This metric captures not only absolute adoption numbers but also the critical time dimension of launch performance, reflecting the rate at which clinical practice change propagates through professional networks. Previous research has established uptake velocity as a more reliable predictor of long-term market success than conventional metrics such as sales volume alone, particularly in complex therapeutic categories where clinician education represents a significant adoption barrier [8].

Educational reach constituted the second key performance indicator, measured as the share of unique healthcare professionals exposed to at least one verified message touchpoint regarding the therapeutic innovation. This metric extends beyond mere message delivery to verify actual engagement with key scientific messaging, a crucial distinction in contemporary pharmaceutical education where attention scarcity represents a significant challenge. By tracking verified touchpoints rather than simple outreach attempts, the evaluation captured meaningful educational penetration rather than merely promotional contact volume.

The third critical metric, field-team cost efficiency, was calculated as total engagement spend per incremental adopter, providing a direct measure of resource utilization effectiveness. This economic dimension of launch performance acknowledges the substantial investment required for field-based engagement and the imperative to optimize return on these investments. By normalizing costs against incremental adoption, the metric facilitates direct comparison across therapeutic categories with varying absolute market sizes and engagement requirements.

Analytical rigor was ensured through difference-in-differences regression methodology, incorporating interaction terms for influence rank and sentiment class, with appropriate controls for payer mix and competitive intensity in each therapeutic category. This statistical approach allowed for isolation of the specific impact attributable to the network-based identification framework while accounting for market-specific factors that might otherwise confound interpretation of the results. Sensitivity analyses examined results across multiple timeframes to ensure robustness of findings to temporal variation in market conditions.

4.2 Results

The empirical evaluation demonstrated consistent performance advantages across all three therapeutic launches, with notable consistency in the magnitude of impact despite substantial differences in market context and adoption barriers. The immuno-oncology launch, employing 45 KOLs identified through the propagative-influence methodology, achieved a 31% increase in uptake velocity compared to traditional targeting approaches, alongside a 38% reduction in field engagement costs per incremental adopter. This performance in a complex specialty market with sophisticated prescribers provides particularly compelling evidence for the framework's ability to identify genuine influence pathways in scientifically nuanced therapeutic areas.

The antiviral launch in a pandemic context represented a distinct challenge characterized by accelerated timelines and heightened stakeholder scrutiny. Utilizing 40 KOLs identified through the network-based approach, this launch demonstrated a 26% improvement in uptake velocity compared to conventional methodologies, with a corresponding 33% reduction in field costs. The framework's effectiveness in this high-pressure, time-sensitive context suggests particular value for launches where rapid message dissemination represents a critical success factor.

For the rare metabolic condition launch, the approach identified 54 KOLs and delivered a 30% increase in uptake velocity alongside a 34% reduction in field costs. This performance in a specialized therapeutic area with limited patient populations demonstrates the framework's efficacy even in concentrated markets where each individual prescriber carries disproportionate weight in overall adoption outcomes. The consistent performance across these diverse therapeutic contexts provides compelling evidence for the methodology's broad applicability across the pharmaceutical launch landscape.

Perhaps most striking among the empirical findings was the pronounced sentiment effect on prescription generation. Networks led by positively trending KOLs generated 774 prescriptions per leader, 3.5 times more than neutral networks and 9.2 times more than negative networks with otherwise comparable influence profiles. This dramatic differential underscores the critical importance of attitudinal factors in modulating influence effectiveness and validates the framework's emphasis on sentiment surveillance alongside network position. The practical significance of this finding was further demonstrated through targeted resource reallocation: by directing just 15% of field visits toward these high-value networks characterized by positive sentiment trajectories, companies achieved an 11% increase in year-one adopter counts without requiring additional budget allocation. This resource optimization represents a particularly valuable outcome in an era of increasing pressure on pharmaceutical commercial resources and growing emphasis on launch efficiency.

Journal of Information Systems Engineering and Management
2025, 10(60s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/
Research Article



Fig 3: Empirical Validation of Network-Based KOL Identification Framework [7, 8]

5. Implementation Framework

Successful operationalization of the network-based influence identification framework requires thoughtful integration into existing pharmaceutical organizational structures and workflows. Implementation experience across multiple companies suggests that several critical operational components must be established to maximize the framework's impact while ensuring appropriate governance and compliance. The transition from traditional KOL identification approaches to this more sophisticated methodology necessitates not merely technological deployment but comprehensive organizational adaptation spanning multiple functional areas and requiring executive-level championship.

Effective cross-functional governance represents perhaps the most fundamental prerequisite for successful implementation. Unlike traditional approaches that often operate in functional silos, with medical affairs, marketing, and commercial teams maintaining separate and sometimes conflicting KOL lists, the network-based framework requires unified ownership of influence-sentiment outputs across departments. This shared governance model ensures aligned outreach strategies and content development, preventing the fragmentation that frequently undermines launch effectiveness. Research examining pharmaceutical organizational structures has identified siloed KOL engagement as a significant barrier to consistent messaging and relationship development, with cross-functional governance models demonstrating superior outcomes in terms of both educational impact and compliance adherence [9]. Leading implementations establish formal governance committees with representation from medical affairs, marketing, market access, and compliance functions, meeting monthly to review network insights and coordinate engagement strategies.

The dynamic nature of influence networks and sentiment trajectories necessitates a regular refresh cadence to maintain actionable relevance. Quarterly system updates have emerged as the optimal frequency, balancing the need for current data against the operational disruption of more frequent revisions. This quarterly rhythm enables the system to capture market shocks from major data releases, congress presentations, or competitor announcements, supporting agile resource re-prioritization as the competitive landscape evolves. The implementation methodology incorporates structured processes for accommodating these periodic updates, including standardized data validation protocols, version control procedures, and change management communications to ensure field teams can effectively incorporate new network insights into their engagement strategies. This systematic approach to knowledge updating addresses a recognized limitation of traditional KOL identification methods, which often remain static despite rapidly evolving market conditions and scientific developments.

Technological integration represents another critical implementation dimension, with leading organizations embedding network analytics directly into existing commercial infrastructure rather than creating standalone systems. Customer relationship management (CRM) platforms serve as the primary integration point, with influence rank, sentiment trajectory, confidence scores, and explanatory drill-downs incorporated directly into the field-facing interfaces used by medical science liaisons and account managers. This integration enables real-time decision-making during territory planning and engagement preparation, putting network insights at the point of action rather than confined to separate analytical environments. Modern implementations leverage application programming interfaces (APIs) to maintain synchronization between the network analytics engine and downstream systems, ensuring field teams always access current influence assessments rather than outdated snapshots.

Robust compliance safeguards constitute the final essential implementation component, particularly given the heightened regulatory scrutiny surrounding pharmaceutical engagement with healthcare professionals. The framework incorporates several structural protections to ensure regulatory compliance, beginning with the fundamental design principle that sentiment scores remain content-agnostic, focusing on general attitude toward therapeutic approaches rather than specific products. This methodological choice prevents the system from being used to target HCPs based on product-specific prescribing likelihood, which would raise significant compliance concerns. Furthermore, comprehensive medical-legal review governs all downstream materials and interactions derived from network insights, with documented approval workflows integrated directly into the engagement planning process. A recent analysis of pharmaceutical compliance frameworks identified this "compliance by design" approach as substantially more effective than post-hoc monitoring in preventing regulatory violations while maintaining commercial effectiveness [10].

The implementation timeline typically spans six to nine months from initial deployment to full operational integration, with a phased approach that begins with limited therapeutic areas before expanding to the full portfolio. This measured rollout enables organizational learning and process refinement while limiting disruption to ongoing commercial activities. Success metrics for implementation typically include adoption rates among field teams, consistency of engagement planning with network insights, and qualitative assessment of cross-functional collaboration improvement. Organizations that have successfully implemented this approach report significant improvements in both the efficiency and effectiveness of their KOL engagement strategies, with particular benefits in complex therapeutic areas where influence pathways are less immediately apparent through traditional identification methods.

Journal of Information Systems Engineering and Management
2025, 10(60s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/

Research Article



Fig 4: Implementation Framework for Network-Based KOL Identification [9, 10]

Conclusion

This hybrid approach—combining generative AI with human medical expertise, layered onto multi-source influence analytics—represents a significant advancement in pharmaceutical launch strategy. By illuminating both influence pathways and sentiment trajectories, companies can synchronize message timing with behavioral readiness, ultimately achieving faster clinical adoption and more efficient resource allocation. As digital discourse continues to grow in volume and complexity, and as therapeutic classes proliferate, this combined network-and-sentiment methodology provides pharmaceutical companies with an adaptable framework for optimizing future launch strategies. The demonstrated performance improvements suggest that influence-based targeting, informed by sentiment analysis, may become the new standard for pharmaceutical market engagement.

References

[1] ExtendMed, "KOL Management in Pharma: A Complete Guide (2025)," ExtendMed, 2025. [Online]. Available: https://www.extendmed.com/news-and-resources/kol-management
[2] Letícia Miquelitto Gasparoni et al., "The influence of social networks on finding and selecting healthcare professionals," Brazilian Oral Research, 2025. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC11729411/

Journal of Information Systems Engineering and Management
2025, 10(60s)
e-ISSN: 2468-4376
https://www.jisem-journal.com/
Research Article

[3] Spershika Srivastava, "Key Opinion Leader Mapping: An Essential Strategy for Pharma Success," AISSEL Blog, 2025. [Online]. Available: https://www.aissel.com/blog/key-opinion-leader-mapping-an-essential-strategy-for-pharma-success/
[4] James Dearing et al., "Project Echo Review and Research Agenda," ResearchGate, 2019. [Online]. Available:
https://www.researchgate.net/publication/331321004_PROJECT_ECHO_Review_and_Research_Agenda
[5] M. E. J. Newman, "Networks: An Introduction," Oxford University Press, 2010. [Online]. Available: https://math.bme.hu/~gabor/oktatas/SztoM/Newman_Networks.pdf
[6] Eytan Bakshy et al., "The Role of Social Networks in Information Diffusion," arXiv:1201.4145, 2012. [Online]. Available: https://arxiv.org/abs/1201.4145
[7] Partha Anbil and Kamini Anbil, "Simulated Pre-Launch Market Evaluation in the Modern Pharmaceutical Industry," Pharmaceutical Executive, 2025. [Online]. Available: https://www.pharmexec.com/view/simulated-pre-launch-market-evaluation-modern-industry
[8] Eun Ji Kim et al., "Process Analytical Technology Tools for Monitoring Pharmaceutical Unit Operations: A Control Strategy for Continuous Process Verification," Pharmaceutics, 2021. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC8234957/
[9] Olivia McDermott et al., "Barriers and Enablers for Continuous Improvement Methodologies within the Irish Pharmaceutical Industry," ResearchGate, 2021. [Online]. Available: https://www.researchgate.net/publication/357420915_Barriers_and_Enablers_for_Continuous_Improvement_Methodologies_within_the_Irish_Pharmaceutical_Industry
[10] KPMG, "Compliance by Design," KPMG. [Online]. Available: https://assets.kpmg.com/content/dam/kpmg/ie/pdf/2022/10/ie-compliance-by-design.pdf